Abstract | AIMS AND BACKGROUND: METHODS: Sixty patients treated with cisplatin-containing regimens were entered into a randomized, double-blind study with cross-over. Lorazepam 2.5 mg or placebo were administered orally the evening before therapy and just after the beginning of fluid infusion for chemotherapy. Degree of nausea and number of vomiting episodes, together with somnolence, were recorded on a data flow sheet and visual-analogue scales. RESULTS: 100 cycles (50 patients) are evaluable. In 39 cycles there was no nausea and vomiting, in 74 cycles acceptable control of emesis was reached (0-2 episodes of vomiting), without significant differences among the two arms. However, nausea was shorter in lorazepam arm (p < 0.01), and 80% of the patients preferred treatment with lorazepam (p < 0.003). Anxiety was reduced in the patients treated with lorazepam (p < 0.4). CONCLUSIONS:
Lorazepam improves tolerability to cisplatin-containing chemotherapy, mainly by influencing the psychological status of the patient and favoring the amnestic process.
|
Authors | M Clerico, O Bertetto, M P Morandini, C Cardinali, G Giaccone |
Journal | Tumori
(Tumori)
Vol. 79
Issue 2
Pg. 119-22
(Apr 30 1993)
ISSN: 0300-8916 [Print] United States |
PMID | 8346563
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Metoclopramide
- Lorazepam
- Cisplatin
- Methylprednisolone
|
Topics |
- Adult
- Aged
- Cisplatin
(adverse effects)
- Double-Blind Method
- Drug Therapy, Combination
- Female
- Humans
- Lorazepam
(administration & dosage)
- Male
- Methylprednisolone
(administration & dosage)
- Metoclopramide
(administration & dosage)
- Middle Aged
- Neoplasms
(drug therapy)
- Vomiting
(chemically induced, prevention & control)
|